Abstract:
Ever since the discovery of very first chemotherapeutic drug, questions were
raised regarding its not so popular and almost ubiquitous side effects. There always exists
a delicate balance between efficacy, tolerability and undesirable effects for any particular
drug, depending mainly upon its dosages and duration of its therapeutic regime. The
success of a drug thus not only depends upon its potential to combat the impeding
diseased state but also in its ability to refrain from any undesired toxicity. Not
surprisingly, the reason for withdrawal of nearly 70% of marketed dugs and failure of
new drug entities in pre-clinical and clinical trials is indeed due to drug induced toxicity
(Lee , 2003). This has bestowed pharmaceutical companies with much financial burden
resulting in the quest for more profound and thorough toxicological investigations for
candidate drugs.
The toxicological investigations are primarily concerned with defining the
potential of natural and synthetic substances to produce adverse health effects and to
determine their nature, incidence, mechanism of action and reversibility. However recent
advances in genome-scale sequencing have enabled the development of methods for
quantitatively comparing the expression levels of all potentially expressed genes between
different toxicological samples [Brown & Botstein, 1999]. The application of such
technology to toxicology is known as toxicogenomics. Toxicogenomics has proved to be
a powerful tool for the direct monitoring of patterns of cellular perturbations in specific
pathways through identification and quantification of global shifts in gene expression
resulting from pathological alterations within cells and tissues. In particular,
toxicogenomic technologies using a DNA microarray profile the cell-wide changes in
gene expression following exposure to a toxin. This creates the potential of a
characteristic gene expression profile termed a ‘molecular signature’ or ‘fingerprint’ of
exposure for toxicological response to specific classes of toxic compounds. The
molecular signatures of cellular responses offer the opportunity to: (a) provide
mechanistic information about the cellular perturbations, pathways and responses elicited
by specific exposures (in comparison with responses associated with previously
characterized mechanisms), (b) allow classification of compounds based on the biological
responses they elicit and (c) identify biomarkers specific to particular classes of molecular damage (Murata et al., 1999; Pennie, 2000; Steiner & Anderson, 2000; Waring
2001; Hamadeh et al., 2002).
Malaria remains to be the major killer disease in the developing countries that
affects lives of more than 500 million people annually and killing not less than 2 million
of them (Snow et al., 2005 ).The four species of Plasmodium a protozoan parasite that
causes malaria are P.falciparum, P.ovale, P.malariae, and P.vivax. However major
episodes of the disease are caused by P.falciparum and P.vivax. Most of the drugs that
are used to treat malaria can be broadly grouped into 4-aminoquinilines, 8-
aminoquinilines, anti folates, and artemesinin derivatives. Drugs that are used to treat the
acute attack of malaria acts as blood schizonticidal agents and includes 4-
aminoquinilines, antifolates and artemisinin derivatives. 8-aminoquinilines are tissue
schizonticidal agents and offers a radical cure for malaria by acting on the parasite in
liver (Newton et al.,1999). 4-Aminoquiniline derivatives such as Chloroquine and
Amodiaquine are the first line drugs against malaria for last several decades.
Development of resistance against these drugs in several parts of world necessitated the
use of other drugs along with it for efficient treatment. Sulphadoxine-Pyrimethamine and
Chloroquine/Amodiaquine combination is shown to be very effective against
Chloroquine resistant uncomplicated malaria. (Sowunmi, 2002; Lederman et al., 2006).
However, some reports have shown that certain antimalarial compounds are responsible
for toxicities of different organs. In this regard antimalarial compounds such as quinidine
(Dzur, 1976), quinine (Farver and Lavin, 1999) and chloroquine (Pari and Murugavel,
2004) have been reported to show hepatotoxicity and nephrotoxicity in different
experimental animals. There have been no studies till date to envisage the toxicity profile
of co-exposure of 4-aminoquinilines and anti-folates in experimental animals.
Liver and kidney are the two vital organs of body linked directly with drug
metabolism and their biotransformation. Their unique position and crucial link with
gastro-intestinal tract renders them highly vulnerable to drug induced toxicity. It has been
observed that certain therapeutics whose bio-transformation take place in liver and
kidney often results in the production of toxic by-products. These unwanted by-products
often attain considerable concentration in hepatic and renal tissue, consequently resulting
in target organ toxicity with a number of debilitating effects and breakdown of general body homeostasis. Furthermore, drug-induced toxicity may show exaggerated symptoms
in certain populations due to idiosyncratic behavior (Lee , 2003). Due to these reasons,
drug-induced hepatotoxicity and nephrotoxicity are great clinical problem and a
significant cause of drug withdrawal from marketplaces. To address these issues, robust
screening assays with high predictive capacity are desirable that may be utilized
throughout the drug discovery and development phases in conjunction with traditional in
vivo methods, for decision making during drug selection and risk assessment.
The present endeavor is thus taken to delineate the toxicity and genomic scale
changes in gene expression in mice models exposed with therapeutic equivalent dosages
of antimalarials- amodiaquine and sulfodoxine -pyrimethamine combination. The idea
was to generate antimalarial drug specific toxicity gene expression profile of liver and
kidney tissues capable enough for toxicology class prediction and deciphering
mechanism of antimalarial drug toxicity. Attempts were also made to explain the dose
dependent toxicity of another widely used 4-Aminoquinilline antimalarial drug
Chloroquine in Swiss albino mice. Markers of oxidative stress and changes in gene
expression of major antioxidant enzymes in target organs were studied in light of
previous reports of Chloroquine induced oxidative stress in liver and kidney.
Furthermore, there have been several reports of multi-organ failure including damage to
liver and kidney tissues during malarial infections (Newton & White, 1999; Guha et
al.,2006; Guha et al 2007). The reasons for these damages are not yet clearly understood.
Hence, efforts were also made to understand the probable mechanism of this toxicity in
liver and kidney tissue of host organism. Mouse model has been utilized extensively in
the malaria research to study the pathogenesis, host- parasite interaction, vaccine
development and drug toxicity (Lamb et al.,2006;Wykes & Good,2009;Langhorne et al.,
2002). I infected the mouse model with Plasmodium vinckei petteri a rodent’s malaria
parasite and studied the toxicity and global gene expression alteration with rising level of
percent parasitemia. Plasmodium vinckei petteri infected mice exhibit symptoms and
physiological characteristics similar to human malaria, hence used extensively as good
model for human malaria (Puri et al., 2006).